Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Aaron Jones

Nurse Practitioner, Psychiatric/Mental Health Nashville, TN Nurse Practitioner

NPI 1700555398 CMS profile 10763732

2400 White Ave, Nashville, TN 37204

Open in the dashboard

General payments

$20,205

418 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aaron Jones of Nashville, TN is reported in the CMS Open Payments database as having received $20,205 across 418 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,629 157
2024 General $2,084 121
2023 General $1,211 79
2022 General $1,281 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aaron Jones
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Aaron Jones were reported at $15,629. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Aaron Jones Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $166 $54–$482 $132
2022 $1,281 $195 $66–$559 $149
2023 $1,211 $233 $82–$673 $160
2024 $2,084 $236 $84–$688 $164
2025 $15,629 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Janssen Pharmaceuticals, Inc $13,656 49 payments
  2. Supernus Pharmaceuticals, Inc. $1,103 101 payments
  3. Alkermes, Inc. $1,086 53 payments
  4. Teva Pharmaceuticals USA, Inc. $1,060 57 payments
  5. Neurocrine Biosciences, Inc. $985 46 payments
  6. ITI, Inc. $562 24 payments
  7. Vanda Pharmaceuticals Inc. $463 22 payments
  8. Otsuka America Pharmaceutical, Inc. $343 18 payments
  9. E.R. Squibb & Sons, L.L.C. $254 12 payments
  10. Sunovion Pharmaceuticals Inc. $122 7 payments
  11. Other $569 29 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,100 7 payments
  2. Food and Beverage $7,366 404 payments
  3. Travel and Lodging $659 6 payments
  4. Education $80 1 payment
Products named General payments · program years 2022–2025
  1. INVEGA SUSTENNA $13,592 45 payments
  2. INVEGA TRINZA $12,759 13 payments
  3. ARISTADA Cns $1,023 50 payments
  4. ARISTADA Cns $1,023 50 payments
  5. LYBALVI $1,011 50 payments
  6. INGREZZA $985 46 payments
  7. ARISTADA Cns $792 37 payments
  8. ARISTADA Cns $792 37 payments
  9. Qelbree $766 75 payments
  10. FANAPT $463 22 payments
  11. Other $4,381 235 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

3,006

Median for Nurse Practitioner: 389

Drug cost

$713,402

Median for Nurse Practitioner: $21,885

Branded share of claims

16.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 24 $185,077
Austedo Xr Deutetrabenazine Brand 26 $153,510
Invega Sustenna Paliperidone Palmitate Brand 43 $111,658
Austedo Deutetrabenazine Brand 12 $68,211
Risperdal Consta Risperidone Microspheres Brand 32 $55,029
Aristada Aripiprazole Lauroxil Brand 13 $37,589
Aripiprazole Generic 90 $16,315
Lurasidone Hcl Generic 44 $12,111
Trintellix Vortioxetine Hydrobromide Brand 17 $11,278
Quetiapine Fumarate Generic 199 $4,937

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$10,436

Medicare's payments for the services billed

Medicare patients

40

Average age 60

Services billed

178

21 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Depression 48%
Diabetes 28%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $474
$474 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $210
$210 24 —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $208
$208 43 —
CAPLYTA
  • ITI, Inc. $189
$189 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $160
$160 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

418 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record